{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bochaton T"],"funding":["ANR","Société Francaise de Cardiologie","RHU"],"pagination":["e0245684"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7842962"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(1)"],"pubmed_abstract":["<h4>Introduction</h4>Myocardial hemorrhage (IMH) and persistent microvascular obstruction (MVO) are associated with impaired myocardial recovery and adverse clinical outcomes in STEMI patients. However, their relationship with circulating inflammatory biomarkers is unclear in human patients.<h4>Methods and results</h4>Twenty consecutive patients referred for primary percutaneous coronary intervention of first STEMI were included in a prospective study. Blood sampling was performed at admission, 4, 12, 24, 48 hours, 7 and 30 days after reperfusion for inflammatory biomarker (C reactive protein, fibrinogen, interleukin-6 (IL-6) and neutrophils count) assessment. At seven days, cardiovascular magnetic resonance (CMR) was performed for infarct size, MVO and IMH assessment. Median infarct size "],"journal":["PloS one"],"pubmed_title":["Association of myocardial hemorrhage and persistent microvascular obstruction with circulating inflammatory biomarkers in STEMI patients."],"pmcid":["PMC7842962"],"funding_grant_id":["ANR-10-IBHU-0004 OPeRa","ANR-16- RHUS-0009","Bourse René Foudon"],"pubmed_authors":["Dufay N","Cartier R","Croisille P","Lassus J","Crola Da Silva C","Espanet S","de Bourguignon C","Prieur C","Paccalet A","Bochaton T","Bernelin H","Amaz C","Ovize M","Bonnefoy-Cudraz E","Mewton N","Derimay F","Rioufol G"],"additional_accession":[]},"is_claimable":false,"name":"Association of myocardial hemorrhage and persistent microvascular obstruction with circulating inflammatory biomarkers in STEMI patients.","description":"<h4>Introduction</h4>Myocardial hemorrhage (IMH) and persistent microvascular obstruction (MVO) are associated with impaired myocardial recovery and adverse clinical outcomes in STEMI patients. However, their relationship with circulating inflammatory biomarkers is unclear in human patients.<h4>Methods and results</h4>Twenty consecutive patients referred for primary percutaneous coronary intervention of first STEMI were included in a prospective study. Blood sampling was performed at admission, 4, 12, 24, 48 hours, 7 and 30 days after reperfusion for inflammatory biomarker (C reactive protein, fibrinogen, interleukin-6 (IL-6) and neutrophils count) assessment. At seven days, cardiovascular magnetic resonance (CMR) was performed for infarct size, MVO and IMH assessment. Median infarct size ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2026-04-08T08:07:25.52Z","creation":"2025-04-04T13:05:25.671Z"},"accession":"S-EPMC7842962","cross_references":{"pubmed":["33507957"],"doi":["10.1371/journal.pone.0245684"]}}